Literature DB >> 26416797

Preparation of intravenous cholesterol tracer using current good manufacturing practices.

Xiaobo Lin1, Lina Ma1, Susan B Racette2, William P Swaney3, Richard E Ostlund4.   

Abstract

Studies of human reverse cholesterol transport require intravenous infusion of cholesterol tracers. Because insoluble lipids may pose risk and because it is desirable to have consistent doses of defined composition available over many months, we investigated the manufacture of cholesterol tracer under current good manufacturing practice (CGMP) conditions appropriate for phase 1 investigation. Cholesterol tracer was prepared by sterile admixture of unlabeled cholesterol or cholesterol-d7 in ethanol with 20% Intralipid(®). The resulting material was filtered through a 1.2 micron particulate filter, stored at 4°C, and tested at time 0, 1.5, 3, 6, and 9 months for sterility, pyrogenicity, autoxidation, and particle size and aggregation. The limiting factor for stability was a rise in thiobarbituric acid-reacting substances of 9.6-fold over 9 months (P < 0.01). The emulsion was stable with the Z-average intensity-weighted mean droplet diameter remaining at 60 nm over 23 months. The zeta potential (a measure of negative surface charge protecting from aggregation) was unchanged at -36.2. Rapid cholesterol pool size was 25.3 ± 1.3 g. Intravenous cholesterol tracer was stable at 4°C for 9 months postproduction. CGMP manufacturing methods can be achieved in the academic setting and need to be considered for critical components of future metabolic studies.
Copyright © 2015 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  cholesterol/metabolism; clinical trials; coronary heart disease; deuterium; heart; lipids; mass spectrometry; reverse cholesterol transport; sterols

Mesh:

Substances:

Year:  2015        PMID: 26416797      PMCID: PMC4655978          DOI: 10.1194/jlr.D061762

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  16 in total

Review 1.  Injectable lipid emulsions-advancements, opportunities and challenges.

Authors:  Ketan Hippalgaonkar; Soumyajit Majumdar; Viral Kansara
Journal:  AAPS PharmSciTech       Date:  2010-10-26       Impact factor: 3.246

2.  Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?

Authors:  Surajit Das; Wai Kiong Ng; Reginald B H Tan
Journal:  Eur J Pharm Sci       Date:  2012-06-01       Impact factor: 4.384

3.  The phase behavior of hydrated cholesterol.

Authors:  C R Loomis; G G Shipley; D M Small
Journal:  J Lipid Res       Date:  1979-05       Impact factor: 5.922

4.  Terminal 100 degrees C dry-heat treatment of intravenous immunoglobulin preparations to assure sterility.

Authors:  A I Rubinstein; D B Rubinstein; W Tom
Journal:  Vox Sang       Date:  1994       Impact factor: 2.144

5.  Physicochemical and safety evaluation of 5-aminolevulinic acid in novel liposomes as carrier for skin delivery.

Authors:  Yi-Ping Fang; Pao-Chu Wu; Yi-Hung Tsai; Yaw-Bin Huang
Journal:  J Liposome Res       Date:  2008       Impact factor: 3.648

6.  Fate of intravenously administered particulate and lipoprotein cholesterol in the rat.

Authors:  A Nilsson; D B Zilversmit
Journal:  J Lipid Res       Date:  1972-01       Impact factor: 5.922

7.  Interpretation of the thiobarbituric acid reactivity of rat liver and brain homogenates in the presence of ferric ion and ethylenediaminetetraacetic acid.

Authors:  K Kikugawa; T Kojima; S Yamaki; H Kosugi
Journal:  Anal Biochem       Date:  1992-05-01       Impact factor: 3.365

8.  The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis.

Authors:  Daniel J Rader; Eric T Alexander; Ginny L Weibel; Jeffrey Billheimer; George H Rothblat
Journal:  J Lipid Res       Date:  2008-12-08       Impact factor: 5.922

9.  Systematic characterization of oil-in-water emulsions for formulation design.

Authors:  I Roland; G Piel; L Delattre; B Evrard
Journal:  Int J Pharm       Date:  2003-09-16       Impact factor: 5.875

10.  [13C]cholesterol as a tracer for studies of cholesterol metabolism in humans.

Authors:  R E Ostlund; D E Matthews
Journal:  J Lipid Res       Date:  1993-10       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.